OncLive TV

Linda T. Vahdat, MD, from the Weill Cornell Medical College, discusses the combination of eribulin mesylate and trastuzumab as a first-line therapy for HER2-positive metastatic breast cancer.

Ashish M. Kamat, MD, from MD Anderson Cancer Center, discusses enhancing clinical trial recruitment through a novel definition of BCG therapy failure in patients with nonmuscle invasive bladder cancer.

Emmanuel Antonarakis, MBBCh, from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses the TAXYNERGY trial that is exploring molecular markers of response in men with mCRPC following an early switch in taxane-based treatment.

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the pros and cons of maintenance therapy for patients with myeloma.

Axel Grothey, MD, from the Mayo Clinic in Rochester, Minnesota, discusses the effectiveness of bevacizumab beyond disease progression in metastatic colorectal cancer.

Christopher Twelves, MD, Professor and Honorary Consultant in Medical Oncology, University of Leeds, highlights key findings from the 2012 San Antonio Breast Cancer Symposium, which took place in December 2012.

Deepak A. Kapoor, MD, president of the Large Urology Group Practice Association, discusses the greater exposure to high-quality healthcare that is provided by the integration of ancillary services into community urology practices.

Matthew D. Galsky, MD, from the Mount Sinai Medical Center Tisch Cancer Institute, discusses the development of a post-treatment prognostic model for patients with metastatic urothelial cancer.

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses gauging response in chronic lymphocytic leukemia.

Richard Kim, MD, medical oncologist, Gastrointestinal Oncology Department at Moffitt Cancer Center, discusses the use of ziv-aflibercept (Zaltrap) for patients with metastatic colorectal cancer.

Robert H. Weiss, MD, from the UC Davis Comprehensive Cancer Center, discusses peroxisome PPAR-alpha as a possible new treatment target for patients with renal cell carcinoma.

William J. Gradishar, MD, from the Northwestern University Feinberg School of Medicine, describes the need to enrich the patient population in a clinical trial that is investigating a novel targeted therapy.

Francesco Lo-Coco, MD, Hematology, University Tor Vergata, discusses a new emerging treatment, arsenic trioxide (ATO), in acute promyelocytic leukemia (APL).

Edith A. Perez, MD, from the Mayo Clinic Cancer Center, discusses the antibody-drug conjugate T-DM1 that is being investigated as a treatment for patients with HER2-positive, unresectable, locally advanced or metastatic breast cancer.

Michelle A. Fanale, MD, from the MD Anderson Cancer Center, discusses the potential of antibody-drug conjugates, as a new category of therapy for patients with cancer.

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses results from the ATLAS trial that compared 5 years of adjuvant tamoxifen to 10 in patients with estrogen receptor-positive early breast cancer.

Ghassan K. Abou-Alfa, MD, from Memorial Sloan-Kettering Cancer Center, discusses the promising results and future investigation of MET inhibition in hepatocellular carcinoma using cabozantinib and tivantinib.

William J. Gradishar, MD, from the Northwestern University Feinberg School of Medicine, describes results from the 301 Study that compared eribulin mesylate to capecitabine for locally advanced or metastatic breast cancer.

Johanna Bendell, MD, Director of GI Cancer Research Program, Associate Director, Drug Development Program, Sarah Cannon Research Institute, discusses c-MET inhibition in hepatocellular carcinoma.

Peter A. Kaufman, MD, Associate Professor of Medicine at the Geisel School of Medicine at Dartmouth, discusses the side effect profiles of the microtubule inhibitor eribulin mesylate and the oral chemotherapeutic agent capecitabine.

Axel Grothey, MD, from the Mayo Clinic, Rochester, Minnesota, discusses a survey that examined the perceived benefits and use of adjuvant oxaliplatin in colon cancer.

Eleftherios (Terry) P. Mamounas, MD, MPH, from the Aultman Hospital Cancer Center, discusses the controversial topic of surgery for patients who present with stage IV breast cancer at the time of diagnosis.

James R. Berenson, MD, discusses a phase I/II study of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma.

James C. Yao, MD, from the MD Anderson Cancer Center, describes the administration of the mTOR inhibitor everolimus in patients with pancreatic neuroendocrine tumors.

Jorge E. Cortes, MD, Department of Leukemia, University of Texas, MD Anderson Cancer Center, discusses the use of ponatinib as initial therapy for patients with chronic myeloid leukemia.

Debu Tripathy, MD, from the University of Southern California Norris Comprehensive Cancer Center, discusses the final analysis of overall survival for the phase III CONFIRM trial.

Jason A. Konner, MD, Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the uncertain path of PARP inhibitors for the treatment of ovarian cancer.

Paul Ruff, MD, from the Witwatersrand, Johannesburg, South Africa, discusses a time-course analysis of overall survival following treatment with ziv-aflibercept in patients with metastatic colorectal cancer, as observed in the VELOUR trial.

Richard Kim, MD, medical oncologist, Gastrointestinal Oncology Department at Moffitt Cancer Center, discusses studies investigating regorafenib (Stivarga) in metastatic colorectal cancer.

James Mohler, MD, Roswell Park Cancer Institute, explains the progress needed to better understand androgen receptors.